Literature DB >> 19211031

Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.

Paola Rocca1, Cristiana Montemagni, Filomena Castagna, Michela Giugiario, Mara Scalese, Filippo Bogetto.   

Abstract

The purpose of this study was to examine the relative contributions of antipsychotic medication, negative symptoms and executive functions to impairment in social functioning in a sample of outpatients with stable schizophrenia. One-hundred and sixty-eight consecutive outpatients with stable schizophrenia were enrolled in a cross-sectional study. We performed a path analysis using multiple regression technique in order to assess the specific effect of antipsychotic type (first-generation antipsychotics versus second-generation antipsychotics) on social functioning and the possible mediating role of executive functions and negative symptoms. Our findings suggested that (i) second generation antipsychotics (SGAs) use predicted better social functioning (Beta=.24, p=.003) and better executive functions (Beta=.25, p=.003); conversely SGAs use was not associated with lesser negative symptoms (Beta=.00, p=.981); (ii) impaired executive functions and severity of negative symptoms were associated with worse social functioning (Beta=.19, p=.016; Beta=.28, p=.001); (iii) when we inserted in the model Positive and Negative Syndrome Scale - Negative Symptom subscale (PANSS-N) and Wisconsin Card Sorting Test - number of achieved sorting categories (WCST-cat), the former failed to show a mediation effect, while the latter seemed to mediate partially the effect of SGAs on social functioning. Taken together, the present results suggest that it is critical to examine individually executive functions and negative symptoms because they seem to relate to social functioning in different and independent ways and thus might represent separable treatment targets. Furthermore, social functioning appears a complex outcome multiply determined with no single predictor variable explaining a sufficient amount of variance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211031     DOI: 10.1016/j.pnpbp.2009.01.002

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

1.  Pathways between early visual processing and functional outcome in schizophrenia.

Authors:  Y Rassovsky; W P Horan; J Lee; M J Sergi; M F Green
Journal:  Psychol Med       Date:  2010-05-19       Impact factor: 7.723

2.  Childhood Predictors of Young Adult Social Functioning in 22q11.2 Deletion Syndrome.

Authors:  Kayla E Wagner; Wendy R Kates; Wanda Fremont; Kevin M Antshel
Journal:  J Autism Dev Disord       Date:  2017-08

3.  "Cool" and "Hot" Executive Functions in Patients With a Predominance of Negative Schizophrenic Symptoms.

Authors:  Pamela Ruiz-Castañeda; Encarnación Santiago-Molina; Haney Aguirre-Loaiza; María Teresa Daza González
Journal:  Front Psychol       Date:  2020-11-05

4.  Real-World Functioning in Psychiatric Outpatients: Predictive Factors.

Authors:  Paola Bozzatello; Benedetta Giordano; Cristiana Montemagni; Paola Rocca; Silvio Bellino
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

5.  Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia.

Authors:  Eleni Jelastopulu; Evangelia Giourou; Giorgos Merekoulias; Angeliki Mestousi; Eleftherios Moratis; Evangelos C Alexopoulos
Journal:  BMC Psychiatry       Date:  2014-07-08       Impact factor: 3.630

6.  Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study).

Authors:  Elisabeth Giraud-Baro; Daniel Dassa; Florent De Vathaire; Ricardo P Garay; Joelle Obeid
Journal:  BMC Psychiatry       Date:  2016-01-15       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.